Since the time that we submitted our findings for publication, additional data have emerged supporting a link between these two hormone-dependent malignancies. An article by Monne et al. (6) reports that approximately 30% of female breast tumors produce a protein that is identical to the prostatespecific antigen (PSA) produced by the prostate gland.
We are pleased that Dr. Fleshner is conducting a study that will administer a "comprehensive genetic questionnaire"; it is essential that our observations be repeated in other populations by different investigators. One should remember that attribution of the association solely to genes was not our conclusion. A maternal history of early-onset (<45 years) breast cancer was associated with a borderline statistically significant (relative risk = 1.41; 95% confidence interval = 0.98-2.03) elevated prevalence of prostate cancer in the father. Because these individuals do not share genes, shared environment clearly must be considered as an equally plausible explanation. 
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Role of the Glutathione S-Conjugate Pump in Cisplatin Resistance
Recently, two reports (J 2) suggested that the adenosine triphosphate-dependent glutathione S-conjugate export pump (GS-X pump) is involved in cell lines with acquired cisplatin resistance in vitro. Fujii et al. (/) suggested that the GS-X pump plays a role in the efflux of platinum from their 25-fold cisplatinresistant KCP-4 cells.
By analyzing cell lines that have acquired doxorubicin resistance in vitro and that overexpress the multidrug resistance-associated protein (MRP), as well as cell lines transfected with an MRP-expression vector, we and other investigators recently provided strong evidence that overexpression of MRP results in an increased activity of the GS-X pump .
From the small-cell lung carcinoma cell line GLC4, we derived in vitro a 150-fold doxorubicin-resistant cell line (GLC4/ADR) and an 8.6-fold cisplatinresistant cell line (GLC4/CDDP) (3, [6] [7] [8] . There was an approximately 25-fold increase in MRP messenger RNA in the GLC4/ADR cell line, which parallels the amount of MRP in membrane subfractions as revealed by Western blotting (9). In contrast, no increased MRP level could be detected in plasma membranes of the GLC4/CDDP cell line. As compared with the parental GLC4 cell line, the GS-X pump activity, determined with the substrates leukotriene C4 and dinitrophenyl glutathione, was overexpressed eightfold and sevenfold, respectively, in the GLC4/ADR cell line, but the GLC4/CDDP cell line did not show any overexpression. Despite the extensive overexpression of the GS-X pump in the GLC4/ADR cell line, only a 2.1-fold cross-resistance for cisplatin was observed; however, in the cisplatin-resistant cell line, GLC4/CDDP, no overexpression of the GS-X pump was observed. In addition, the 10-fold cisplatin-resistant cell line of Ishikawa et al. (2) showed no cross-resistance for doxorubicin compared with the parent cell line, while the MRP-transfected cell line of Cole et al. (JO) showed no cross-resistance to cisplatin compared with the original cell line.
These findings underscore the fact that overexpression of the GS-X pump does not necessarily have to result in cisplatin or doxorubicin resistance. The fact that overexpression does not necessarily result in cisplatin resistance suggests that the ultimate effect of the GS-X pump depends on other factors, such as the glutathione system (glutathione, glutathione S-transferase activity, or glutathione peroxidase activity). Ishikawa et al. (2) 
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Recently, we have also isolated the following non-P-glycoprotein-mediated multidrug-resistant cell lines from human epidermoid carcinoma KB cells: C-A120, C-A500, and CA-1000 (7). Multidrug resistance-associated protein (MRP) was expressed in these multidrug-resistant cells, and the membrane vesicles from the cells transported [ 3 H]leukotriene C 4 (LTC 4 ). We therefore examined the expression of MRP and MRP messenger RNA (mRNA) in our cisplatin-resistant KCP-4 cells by immunoblot and slot-blot analysis, respectively. MRP was not detected, and MRP mRNA was not overexpressed in KCP-4 cells. Cross-resistance to cisplatin of our non-P-glycoproteinmediated multidrug-resistant cells was marginal (/) , and cisplatin-resistant KCP-4 cells were not cross-resistant to doxorubicin, daunorubicin, and vincristine (2) . Although the rat liver has a GS-X pump that transports LTC 4 (3,4) , and the GS-X pump is supposedly present in human liver, the expression of MRP mRNA in the human liver was found to be lower than that in KB cells. Taken together, these Findings suggest that the GS-X pump expressed in KCP^ cells is different from MRP and appears to transport LTC 4 . It is probable that GLC4/CDDP cells did not show any overexpression of the GS-X pump, since these cells do not seem to have an active efflux system for cisplatin (5) .
We also noted that the glutathione level was seven times higher in KCP-4 cells than the level in KB cells, but the level of glutathione S-transferase was similar in both cells. The glutathione conjugation reaction may result in the bioactivation of these compounds, as opposed to their detoxification. In addition, the accumulation of the glutathione 5-conjugates in cells may lead to a decrease in the detoxification activity of the conjugation system (6). Ishikawa and Ali-Osman (7) showed that cisplatin conjugated with glutathione, the GSplatinum complex, inhibited protein synthesis in vitro. The export pump for the GS-platinum complex, on the contrary, may play a protective role by decreasing the complex's intracellular concentration. Because the level of GSplatinum complex and its cytotoxic activity in the KCP-4 cells are not known, further study is needed to elucidate whether the GS-X pump is involved in the cisplatin resistance. 
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